Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 352 | 57 | 283 |
| Samples | 333 | 54 | 268 |
| Peptides | 258 | 36 | 221 |
Function
PRKCA · Protein kinase C alpha
Protein kinase C (PKC) is a family of serine- and threonine-specific protein kinases that can be activated by calcium and the second messenger diacylglycerol. PKC family members phosphorylate a wide variety of protein targets and are known to be involved in diverse cellular signaling pathways. PKC family members also serve as major receptors for phorbol esters, a class of tumor promoters. Each member of the PKC family has a specific expression profile and is believed to play a distinct role in cells. The protein encoded by this gene is one of the PKC family members. This kinase has been reported to play roles in many different cellular processes, such as cell adhesion, cell transformation, cell cycle checkpoint, and cell volume control. Knockout studies in mice suggest that this kinase may be a fundamental regulator of cardiac contractility and Ca(2+) handling in myocytes. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 257 amino-acid changes on canonical ENST00000413366 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PRKCA · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PRKCA – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Chordoma | 1/7 14% | 0/13 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 6/133 5% |
| Endometrial Carcinoma | 4/42 10% | 12/612 2% |
| Cervical Carcinoma | 2/35 6% | 9/422 2% |
| Melanoma | 4/210 2% | 42/1899 2% |
| Other Solid Cancers | 0/94 0% | 23/1515 2% |
| Gastric Carcinoma | 0/74 0% | 26/1809 1% |
| Squamous Cell Lung Carcinoma | 3/57 5% | 9/810 1% |
| Small Cell Lung Carcinoma | 1/9 11% | 8/752 1% |
| Non-Small Cell Lung Carcinoma | 3/304 1% | 16/1390 1% |
| Colorectal Carcinoma | 14/143 10% | 22/3239 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Ovarian Carcinoma | 5/109 5% | 5/998 0% |
| Plasma Cell Myeloma | 2/44 5% | 1/305 0% |
| Head and Neck Carcinoma | 2/85 2% | 11/1574 1% |
| Glioma | 2/52 4% | 12/2127 1% |
| Hepatocellular Carcinoma | 0/46 0% | 14/2210 1% |
| Bladder Carcinoma | 0/58 0% | 6/956 1% |
| Non-Cancerous | 0/104 0% | 5/830 1% |
| Pancreatic Carcinoma | 0/89 0% | 9/1611 1% |
| Esophageal Carcinoma | 0/23 0% | 4/769 1% |
| Rhabdomyosarcoma | 0/33 0% | 1/171 1% |
| Osteosarcoma | 0/45 0% | 1/166 1% |
| Medulloblastoma | 0/0 0% | 2/450 0% |
| Meningioma | 0/3 0% | 1/252 0% |
| Breast Carcinoma | 1/144 1% | 12/3264 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 6/2550 0% |
| Biliary Tract Carcinoma | 0/54 0% | 2/950 0% |
| B-Cell Non-Hodgkins Lymphoma | 3/88 3% | 2/2534 0% |
Mutation Distribution
Where PRKCA is mutated · all tissues, split by cell line vs tissue
How many mutations in PRKCA were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 352 mutations in PRKCA
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|